Also trades as: AGIO (NASDAQ) · $vol 31M
0HB0.L LSE
Agios Pharmaceuticals, Inc.
1W: -1.0%
1M: -21.1%
3M: -2.4%
YTD: +3.6%
1Y: -11.4%
3Y: +1.1%
$28.10
+0.16 (+0.57%)
Weekly Expected Move ±14.7%
$20
$24
$28
$32
$36
Overview
News
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.6B
52W Range20.13-35.3493
Volume35
Avg Volume522
Beta0.58
Dividend—
Analyst Ratings
Company Info
CEOBrian Goff
Employees486
SectorHealthcare
IndustryBiotechnology
IPO Date2018-01-29
Websiteagios.com
88 Sidney Street
Cambridge, MA 02139-4169
US
Cambridge, MA 02139-4169
US
617 649 8600
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Latest News
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $41.78 Consensus Target Price from Analysts
Equities Analysts Offer Predictions for AGIO FY2027 Earnings
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down After Analyst Downgrade
SG Americas Securities LLC Increases Position in Agios Pharmaceuticals, Inc. $AGIO
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Cecilia Jones Sells 3,141 Shares
Recent Insider Trades
No insider trades found